NEW YORK (GenomeWeb News) – Diagnostics development firm Nuclea Biotechnologies has closed on a $4.7 million Series B financing round, its President and CEO confirmed to GenomeWeb Daily News.
Patrick Muraca said that the funds will be used for submission of its serum-based fatty acid synthase diagnostic test for prostate cancer to the US Food and Drug Administration for 510(k) clearance. Nuclea anticipates it will submit its application by the end of September, he said.
Muraca declined to identify the participants in the round.
The $4.7 million included $3.5 million in cash and $1.2 million in equity.
The financing was disclosed in a document filed with the US Securities and Exchange Commission on Thursday.
Based in Pittsfield, Mass., Nuclea develops gene, protein, and antibody biomarkers and pharmacogenetic diagnostic assays for predicting effective treatments for certain patients. A month ago, it and Clark University created a new center to use proteomic and metabolomic methods to conduct biomarker research directed at cancer.